Get research updatesSchizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open Label Follow up Trial of RIS-INT-57 and RIS-INT-61.
This study has finished and is no longer accepting participants.
Location not clearly listedRisperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open-label Follow-up Trial of RIS-INT-62 and RIS-INT-85.
This study has finished and is no longer accepting participants.
Location not clearly listedOpen-label Study to Evaluate the Safety and Pharmacokinetics of Single- and Multiple-dose Extended-release OROS Paliperidone in Pediatric Subjects (=10 to =17 Years of Age) With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
This study has finished and is no longer accepting participants.
Location not clearly listed
Shared Decision Making: Ein Kommunikationstraining für Patienten Mit Schizophrenie
This study has finished and is no longer accepting participants.
In MünchenA Randomized Open-Label, Rater Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine
This study has finished and is no longer accepting participants.
Location not clearly listedA Randomized, 6-week, Open-Label, Study Evaluating The Safety, Tolerability, and Efficacy of Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockThis study evaluated the safety of Aripiprazole Lauroxil for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including CerritosA 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (Risperdal� CONSTA�) in Adults With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedA Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating QT/QTc Intervals Following Administration of Extended-release Paliperidone and Quetiapine in Subjects With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedA Placebo- and Positive-controlled, Randomized Study Evaluating QT and QTc Intervals Following Administration of Immediate-release Paliperidone in Subjects With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedA 24-Week, Flexible-Dose, Open-label Extension Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder (Protocol No. D1050290)
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockA Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.